Half-year Results (HY26) and Restated FY25 Results

AI SummaryClose X

SkinBioTherapeutics plc has released its unaudited half-year results for the six months ended 31 December 2025, alongside restated unaudited FY25 results following a board investigation. The investigation concluded that £0.77 million in accrued royalty revenue was inappropriately recognised in the FY25 financial statements, reducing reported revenue from £4.64 million to £3.87 million. The company also identified issues with the timing of bonus and consultancy payments to certain directors. For the six months to December 2025, revenue increased by 37.4% to £2.17 million, while the operating loss decreased slightly to £1.00 million. The company's cash position at the end of December 2025 was £3.1 million. Significant leadership changes have occurred, including the appointment of an interim CEO and the stepping down of the Chairman and a Non-Executive Director. The costs of the board investigation to date are approximately £0.7 million, and the company intends to pursue recovery of these costs.

Disclaimer*

UK 100

Latest directors dealings